89075-33-2 Usage
Chemical class
Imidazole derivatives
Imidazole derivatives are organic compounds that contain a pyridine ring fused with an imidazole ring.
Heterocyclic aromatic rings
Pyridine and imidazole rings
Both rings consist of a combination of carbon and nitrogen atoms, giving the compound its aromatic properties.
2-(2,4-Dichlorophenyl) group
Two chlorine atoms attached to a phenyl ring
The presence of two chlorine atoms on the phenyl ring contributes to the compound's chemical reactivity and properties.
Potential applications
Medicinal chemistry and drug development
The unique structure and chemical properties of 1H-Imidazo[4,5-c]pyridine, 2-(2,4-dichlorophenyl)make it a promising candidate for the development of new pharmaceutical drugs.
Further research and development
Structure and properties
The compound's structure and properties make it an interesting subject for further research in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 89075-33-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,0,7 and 5 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 89075-33:
(7*8)+(6*9)+(5*0)+(4*7)+(3*5)+(2*3)+(1*3)=162
162 % 10 = 2
So 89075-33-2 is a valid CAS Registry Number.
89075-33-2Relevant academic research and scientific papers
Structure-activity relationships of arylimidazopyridine cardiotonics: Discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine
Robertson,Beedle,Krushinski,Pollock,Wilson,Wyss,Hayes
, p. 717 - 727 (2007/10/02)
Recently several noncatecholamine, nonglycoside cardiotonic drugs have been discovered that possess both inotropic and vasodilator activities in experimental animals and man. Prototypical compounds include amrinone, sulmazole, and fenoximone. We investigated the structural requirements necessary for optimal inotropic activity in a series of molecules containing a heterocyclic ring fused to 2-phenylimidazole and discovered that 2-phenylimidazo[4,5-c]pyridines were generally 5-10-fold more potent than analogous 2-phenylimidazo[4,5-b]pyridines (e.g., sulmazole) or 8-phenylpurines. Furthermore, all imidazo[4,5-c]pyridine analogues we tested were orally active; in contrast, only one of the imidazo[4,5-b]pyridine derivatives, sulmazole, was significantly active. One of several highly active compounds in the [4,5-c] series was 50 (LY175326, 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H- imidazo[4,5-c]pyridine hydrochloride). The structure-activity relationship of this series is presented and compared to that of the imidazo[4,5-b]pyridine and purine series.
